David W. J. McGirr
CIK: 0001219023
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (15 total)
- Jun 24, 2026RYTM
RHYTHM PHARMACEUTICALS, INC.
Award(A)DirectRestricted Stock Units
2.3K shares- - Jun 24, 2026RYTM
RHYTHM PHARMACEUTICALS, INC.
Award(A)DirectStock Option (right to buy)
3.7K shares- - Jun 23, 2026RYTM
RHYTHM PHARMACEUTICALS, INC.
Exercise(M)Direct4.7K shares- - Feb 9, 2026INSM
INSMED Inc
Gift(G)Indirect53.4K shares- - Feb 9, 2026INSM
INSMED Inc
Gift(G)Direct53.4K shares- - Jun 24, 2025RYTM
RHYTHM PHARMACEUTICALS, INC.
Award(A)DirectStock Option (right to buy)
7K shares- - Jun 24, 2025RYTM
RHYTHM PHARMACEUTICALS, INC.
Award(A)DirectRestricted Stock Units
4.7K shares- - Jun 18, 2025RYTM
RHYTHM PHARMACEUTICALS, INC.
Exercise(M)Direct4K shares- - Jun 9, 2025XFOR
X4 Pharmaceuticals, Inc
Award(A)Direct1.5K shares- - Jun 4, 2025INSM
INSMED Inc
Sale(S)Direct3K shares at avg. $73.27$220K - Jun 3, 2025RYTM
RHYTHM PHARMACEUTICALS, INC.
Sale(S)Direct55.6K shares at avg. $65.15$3.6M - Jun 3, 2025RYTM
RHYTHM PHARMACEUTICALS, INC.
Sale(S)Direct9.9K shares at avg. $65.64$648K - Jun 3, 2025RYTM
RHYTHM PHARMACEUTICALS, INC.
Exercise(M)Direct65.4K shares at avg. $4.59$300K - Jun 3, 2025INSM
INSMED Inc
Sale(S)Direct3.3K shares at avg. $71.30$232K - May 15, 2025INSM
INSMED Inc
Award(A)Direct5.1K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 24, 2026 |  RYTM RHYTHM PHARMACEUTICALS, INC. | Award(A) Restricted Stock Units | 2,324 | - | - | Direct |
| Jun 24, 2026 | RYTM RHYTHM PHARMACEUTICALS, INC. | Award(A) Stock Option (right to buy) | 3,691 | - | - | Direct |
| Jun 23, 2026 | RYTM RHYTHM PHARMACEUTICALS, INC. | Exercise(M) | 4,712 | - | $0 | Direct |
| Feb 9, 2026 |  INSM INSMED Inc | Gift(G) | 53,400 | - | $0 | Indirect |
| Feb 9, 2026 | INSM INSMED Inc | Gift(G) | 53,400 | - | $0 | Direct |
| Jun 24, 2025 | RYTM RHYTHM PHARMACEUTICALS, INC. | Award(A) Stock Option (right to buy) | 7,037 | - | - | Direct |
| Jun 24, 2025 | RYTM RHYTHM PHARMACEUTICALS, INC. | Award(A) Restricted Stock Units | 4,712 | - | - | Direct |
| Jun 18, 2025 | RYTM RHYTHM PHARMACEUTICALS, INC. | Exercise(M) | 4,000 | - | - | Direct |
| Jun 9, 2025 |  XFOR X4 Pharmaceuticals, Inc | Award(A) | 1,500 | - | - | Direct |
| Jun 4, 2025 | INSM INSMED Inc | Sale(S) | 3,000 | $73.27 | $219,810 | Direct |
| Jun 3, 2025 | RYTM RHYTHM PHARMACEUTICALS, INC. | Sale(S) | 55,558 | $65.15 | $3,619,404 | Direct |
| Jun 3, 2025 | RYTM RHYTHM PHARMACEUTICALS, INC. | Sale(S) | 9,873 | $65.64 | $648,090 | Direct |
| Jun 3, 2025 | RYTM RHYTHM PHARMACEUTICALS, INC. | Exercise(M) | 65,431 | $4.59 | $300,328 | Direct |
| Jun 3, 2025 | INSM INSMED Inc | Sale(S) | 3,250 | $71.30 | $231,725 | Direct |
| May 15, 2025 | INSM INSMED Inc | Award(A) | 5,058 | - | - | Direct |
1-15 of 15 transactions
About MCGIRR DAVID W J
MCGIRR DAVID W J (SEC CIK 0001219023) files insider reports with the SEC as Director of RHYTHM PHARMACEUTICALS, INC. (RYTM), Director of INSMED Inc (INSM) and Director of X4 Pharmaceuticals, Inc (XFOR).
Signal8 holds 8 ownership filings by MCGIRR DAVID W J, all Form 4s, filed between May 19, 2025 and Jun 25, 2026. Those filings report 15 transactions, from May 15, 2025 to Jun 24, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on MCGIRR DAVID W J's filings is in BOSTON, MA.
Recent filings by MCGIRR DAVID W J
- Jun 24, 2026: Grants or awards of RYTM derivative securities (2 lines, Form 4, code A).
- Jun 23, 2026: Option exercise of RYTM shares (Form 4, code M).
- Feb 9, 2026: Gifts of INSM shares (2 lines, Form 4, code G).
- Jun 24, 2025: Grants or awards of RYTM derivative securities (2 lines, Form 4, code A).
- Jun 18, 2025: Option exercise of RYTM shares (Form 4, code M).
Other insiders filing for RHYTHM PHARMACEUTICALS, INC. (RYTM)
- Meeker David P, President and CEO
- Smith Hunter C, Chief Financial Officer
- Joshi Manher, Chief Medical Officer
- Shulman Joseph, Chief Technical Officer
- Garfield Alastair, Chief Scientific Officer
- Lee Jennifer Kayden, EVP, Head of North America